New Synthesized Activating Transcription Factor 3 Inducer SW20.1 Suppresses Resistin-Induced Metabolic Syndrome

Area of Science:

• Biochemistry
• Pharmacology
• Metabolic Diseases

Background:

• Obesity is a global health concern linked to cardiovascular disease, dyslipidemia, and cancer.
• There is an urgent need for novel therapeutic agents to combat rising obesity rates.
• Activating transcription factor 3 (ATF3) plays a role in metabolic regulation.

Purpose of the Study:

• To investigate the antiobesity effects of a novel compound, SW20.1, which induces ATF3 expression.
• To elucidate the molecular mechanisms underlying SW20.1's action on adipogenesis and lipogenesis.
• To evaluate SW20.1's efficacy in preclinical models of diet-induced obesity.

Main Methods:

• In vitro studies using 3T3-L1 preadipocytes to assess lipid accumulation and gene expression.
• Quantitative real-time polymerase chain reaction (qRT-PCR) to measure gene expression levels.
• Chromatin immunoprecipitation (ChIP) assay to identify SW20.1 binding sites on the resistin promoter.
• In vivo studies involving intraperitoneal administration of SW20.1 in diet-induced obese mice.

Main Results:

• SW20.1 significantly reduced lipid accumulation in 3T3-L1 cells compared to ST32db.
• SW20.1 inhibited key genes involved in adipogenesis and lipogenesis.
• ChIP assay revealed SW20.1 binds to specific promoter regions of the resistin gene.
• In mice, SW20.1 decreased body weight, adipocyte weight, serum cholesterol, hepatic steatosis, and serum resistin levels.

Conclusions:

• SW20.1 demonstrates significant antiobesity effects by inhibiting resistin expression through the ATF3 pathway.
• SW20.1 effectively reduces adipogenesis and lipogenesis both in vitro and in vivo.
• SW20.1 represents a promising therapeutic candidate for managing diet-induced obesity.